STOCK TITAN

Boston Scientific Corporation (BSX) Financials

BSX NYSE
Trailing 12 months to September 30, 2026
Revenue $21.1B +8.9% YoY
Net Income $3.5B +25.3% YoY
EPS (Diluted) $2.36 +26.2% YoY
Free Cash Flow $3.3B -12.9% YoY
Market Cap $63.3B as of Nov 18, 2026
Price / Sales 3.0x on $21.1B revenue, trailing 12 months to September 30, 2026
Price / Earnings 18.1x on $3.5B net income, trailing 12 months to September 30, 2026
Price / Book 2.5x on $25.6B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BSX SEC filings page.

Boston Scientific Corporation (BSX) reported $21.1B in revenue over the twelve months to Sep 30, 2026, up 8.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BSX FY2025

Boston Scientific is converting rapid growth into faster profit and cash generation while carrying more debt but improving near-term balance-sheet flexibility.

The key shift is that revenue grew 41.0% from FY2023 to FY2025 while free cash flow grew 104.1%, showing that cash generation accelerated well beyond sales. The free-cash-flow margin reached 18.2% in FY2025 versus 12.6% in FY2023, indicating that more of each sales dollar was becoming discretionary cash after investment.

The balance sheet is expanding with a heavier financing load: long-term debt grew 24.2% in FY2025 while total assets grew 10.9%, pushing debt faster than the asset base. Current ratio moved from 1.1x to 1.6x, so the added borrowing did not translate into tighter reported short-term coverage.

Capital expenditures consumed 19.3% of operating cash flow in FY2025, down from 23.0% in FY2024, so cash generation was not being absorbed by rising reinvestment. R&D grew 27.1% while SG&A grew 15.1%; operating margin nevertheless expanded 2.5 percentage points to 18.0%, consistent with growth absorbing overhead rather than gains coming solely from spending restraint.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 66 / 100
Financial Health Score 66/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Boston Scientific Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
77

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Boston Scientific Corporation scores 77/100 on it among other operating companies.

Growth
80

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Boston Scientific Corporation scores 80/100 on it among other operating companies.

Leverage
46

Boston Scientific Corporation's net debt of $9.2B, being $11.1B of long-term debt less $2.0B of cash, came to 1.84 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Boston Scientific Corporation scores 46/100 among other operating companies measured the same way.

Liquidity
47

Boston Scientific Corporation held $1.62 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.62. Liquidity ranks operating companies on that ratio, and Boston Scientific Corporation scores 47/100 among other operating companies.

Cash Flow
80

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Boston Scientific Corporation scores 80/100 on it among other operating companies.

Returns
65

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Boston Scientific Corporation scores 65/100 on it among other operating companies.

Altman Z-Score Grey Zone
2.96

Boston Scientific Corporation scores 2.96, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $63.3B against total liabilities of $19.4B. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong
7/9

Boston Scientific Corporation passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed
1.56x

For every $1 of reported earnings, Boston Scientific Corporation generates $1.56 in operating cash flow ($4.5B OCF vs $2.9B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
10.35x

Boston Scientific Corporation earns $10.35 in operating income for every $1 of interest expense ($3.6B vs $349.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$5.1B
YoY+1.4%
QoQ-5.6%
5Y CAGR+11.9%
10Y CAGR+9.4%

Boston Scientific Corporation generated $5.1B in revenue in Q3 2026. This represents an increase of 1.4% from the same quarter a year earlier. Against the prior quarter it is down 5.6%.

EBITDA
$1.2B
YoY-14.5%
QoQ-22.4%
5Y CAGR+12.5%
10Y CAGR+8.0%

Boston Scientific Corporation's EBITDA was $1.2B in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.5% from the same quarter a year earlier. Against the prior quarter it is down 22.4%.

Net Income
$582.0M
YoY-22.9%
QoQ-35.8%
5Y CAGR+7.5%
10Y CAGR+9.8%

Boston Scientific Corporation reported $582.0M in net income in Q3 2026. This represents a decrease of 22.9% from the same quarter a year earlier. Against the prior quarter it is down 35.8%.

EPS (Diluted)
$0.40
YoY-21.6%
QoQ-34.4%

Boston Scientific Corporation earned $0.40 per diluted share (EPS) in Q3 2026. This represents a decrease of 21.6% from the same quarter a year earlier. Against the prior quarter it is down 34.4%.

Cash & Balance Sheet

Free Cash Flow
$868.0M
YoY-25.3%
QoQ-32.1%
5Y CAGR+19.4%
10Y CAGRn/m

Boston Scientific Corporation generated $868.0M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 25.3% from the same quarter a year earlier. Against the prior quarter it is down 32.1%.

Cash & Debt
$609.0M
YoY-52.2%
QoQ+13.0%
5Y CAGR-20.7%
10Y CAGR+9.9%

Boston Scientific Corporation held $609.0M in cash against $10.9B in long-term debt as of Q3 2026.

Shares Outstanding
1.45B
YoY-2.2%
QoQ0.0%

Boston Scientific Corporation had 1.45B shares outstanding in Q3 2026. This represents a decrease of 2.2% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
66.7%
YoY-3.2pp
QoQ-4.0pp
5Y change-2.6pp
10Y change-5.4pp

Boston Scientific Corporation's gross margin was 66.7% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 3.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.0 percentage points.

Operating Margin
16.1%
YoY-4.6pp
QoQ-5.5pp
5Y change+2.9pp
10Y change-0.5pp

Boston Scientific Corporation's operating margin was 16.1% in Q3 2026, reflecting core business profitability. This is down 4.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.5 percentage points.

Net Margin
11.3%
YoY-3.6pp
QoQ-5.3pp
5Y change-2.5pp
10Y change+0.5pp

Boston Scientific Corporation's net profit margin was 11.3% in Q3 2026, showing the share of revenue converted to profit. This is down 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.3 percentage points.

Return on Equity
2.3%
YoY-1.0pp
QoQ-1.4pp
5Y change-0.2pp
10Y change-1.3pp

Boston Scientific Corporation's quarterly ROE was 2.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.4 percentage points.

Capital Allocation

R&D Spending
$520.0M
YoY+1.2%
QoQ-6.1%
5Y CAGR+10.9%
10Y CAGR+8.4%

Boston Scientific Corporation invested $520.0M in research and development in Q3 2026. This represents an increase of 1.2% from the same quarter a year earlier. Against the prior quarter it is down 6.1%.

Share Buybacks
$0
YoYn/m

Boston Scientific Corporation repurchased no shares in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Capital Expenditures
$180.0M
YoY-0.6%
QoQ-7.7%
5Y CAGR+11.0%
10Y CAGR+9.7%

Boston Scientific Corporation invested $180.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 0.6% from the same quarter a year earlier. Against the prior quarter it is down 7.7%.

BSX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BSX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$5.1B+1.4%$5.4B+7.5%$5.2B+11.6%$5.3B+15.8%$5.1B+20.3%$5.1B+22.8%$4.7B+20.9%$4.6B+22.5%
Cost of Revenue$1.7B+12.3%$1.6B-2.6%$1.6B+9.4%$1.6B+9.7%$1.5B+16.1%$1.6B+28.9%$1.5B+20.2%$1.5B+27.9%
Gross Profit$3.4B-3.2%$3.8B+12.4%$3.6B+12.6%$3.7B+18.8%$3.5B+22.3%$3.4B+20.1%$3.2B+21.2%$3.1B+20.0%
R&D Expenses$520.0M+1.2%$554.0M+5.3%$516.0M+16.5%$569.0M+24.0%$514.0M+26.3%$526.0M+37.3%$443.0M+21.0%$459.0M+26.8%
SG&A Expenses$1.7B-3.3%$1.8B+5.1%$1.8B+11.5%$1.8B+13.7%$1.7B+11.5%$1.7B+18.7%$1.6B+17.1%$1.6B+16.9%
Operating Income$828.0M-21.0%$1.2B+43.8%$1.1B+19.5%$825.0M+22.2%$1.0B+43.0%$819.0M+57.5%$921.0M+36.4%$675.0M+15.6%
EBITDA$1.2B-14.5%$1.5B+32.7%$1.5B+16.5%$1.2B+16.3%$1.4B+33.8%$1.2B+39.0%$1.2B+27.3%$1.0B+14.0%
Interest Expense$100.0M+14.9%$96.0M+6.7%$90.0M+9.8%$90.0M+12.5%$87.0M+10.1%$90.0M+16.9%$82.0M+18.8%$80.0M+25.0%
Income Tax$153.0M-16.4%$155.0M+6.2%-$176.0M-232.3%$31.0M+34.8%$183.0M-8.5%$146.0M+49.0%$133.0M+15.7%$23.0M+2200.0%
Net Income$582.0M-22.9%$907.0M+13.8%$1.3B+99.0%$672.0M+18.3%$755.0M+61.3%$797.0M+146.0%$674.0M+36.4%$568.0M+12.5%
EPS (Basic)$0.40-21.6%$0.62+14.8%$0.90+95.7%$0.46+21.1%$0.51+59.4%$0.54+145.5%$0.46+35.3%$0.38+11.8%
EPS (Diluted)$0.40-21.6%$0.61+15.1%$0.90+100.0%$0.45+18.4%$0.51+59.4%$0.53+140.9%$0.45+36.4%$0.38+11.8%
Diluted Shares (Avg)1.45B-2.9%1.47B-1.3%1.50B+0.1%N/A1.50B+0.5%1.49B+0.6%1.49B+0.8%N/A

BSX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BSX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$45.5B+6.4%$45.2B+8.8%$44.4B+10.5%$43.7B+10.9%$42.7B+12.2%$41.6B+12.0%$40.1B+9.5%$39.4B+12.1%
Current Assets$8.2B+1.6%$8.0B+12.0%$8.7B+18.4%$8.8B+27.1%$8.0B-8.3%$7.1B-20.8%$7.3B-10.4%$6.9B+6.2%
Cash & Equivalents$609.0M-52.2%$539.0M+0.9%$1.5B+100.4%$2.0B+374.6%$1.3B-49.0%$534.0M-81.7%$725.0M-68.9%$414.0M-52.1%
Short-Term InvestmentsN/AN/AN/AN/A$0n/m$0n/m$0n/m$0n/m
Inventory$3.3B+13.6%$3.2B+13.1%$3.1B+8.7%$2.9B+4.7%$2.9B+6.1%$2.9B+9.7%$2.9B+11.9%$2.8B+13.1%
Long-Term Investments$2.3Bn/m$2.2Bn/mN/A$681.0Mn/m$0n/m$0n/m$0n/m$0n/m
Goodwill$18.7B+2.9%$18.6B+3.1%$18.5B+6.9%$18.3B+7.0%$18.2B+21.2%$18.1B+25.6%$17.3B+20.7%$17.1B+18.8%
Total Liabilities$19.8B+2.7%$20.3B+6.0%$18.5B+3.1%$19.4B+10.3%$19.3B+11.2%$19.1B+14.4%$17.9B+7.1%$17.6B+11.2%
Current Liabilities$6.0B+12.3%$6.4B+23.9%$4.6B-9.6%$5.4B-15.0%$5.3B-9.8%$5.2B-6.9%$5.1B+2.9%$6.4B+29.7%
Non-Current Liabilities$13.8B-1.0%$13.9B-0.7%$13.9B+8.1%$14.0B+24.7%$14.0B+22.0%$14.0B+25.0%$12.9B+8.8%$11.2B+2.8%
Long-Term Debt$10.9B-1.9%$10.9B-1.7%$11.0B+4.3%$11.1B+24.2%$11.1B+20.4%$11.1B+23.5%$10.5B+10.5%$9.0B+4.6%
Total Equity$25.6B+9.6%$24.9B+11.2%$25.9B+16.4%$24.2B+11.3%$23.4B+13.0%$22.4B+10.0%$22.2B+11.5%$21.8B+12.9%
Retained Earnings$8.4B+71.5%$7.8B+88.7%$6.9B+106.5%$5.6B+108.4%$4.9B+132.5%$4.1B+152.8%$3.3B+154.7%$2.7B+226.4%

Not reported in any period shown, so not listed: Accounts Receivable.

BSX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BSX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$1.0B-22.0%$1.5B+14.6%$348.0M-35.7%$1.4B-6.3%$1.3B+34.0%$1.3B+58.2%$541.0M+229.9%$1.5B+52.1%
Depreciation & Amortization$361.0M+5.6%$355.0M+5.7%$351.0M+8.0%$365.0M+4.9%$342.0M+11.8%$336.0M+8.0%$325.0M+6.9%$348.0M+11.2%
Stock-Based CompensationN/AN/A$83.0M+12.2%N/AN/AN/A$74.0M+17.5%N/A
Capital Expenditures$180.0M-0.6%$195.0M+24.2%$177.0M-5.3%$351.0M+26.7%$181.0M+1.1%$157.0M+1.3%$187.0M+4.5%$277.0M+3.7%
Free Cash Flow$868.0M-25.3%$1.3B+13.3%$171.0M-51.7%$1.0B-14.1%$1.2B+41.2%$1.1B+71.6%$354.0Mn/m$1.2B+70.9%
Investing Cash Flow-$437.0Mn/m-$2.0Bn/m-$591.0Mn/m-$512.0Mn/m-$502.0Mn/m-$1.1Bn/m-$500.0Mn/m-$3.7Bn/m
Financing Cash Flow-$569.0Mn/m-$410.0Mn/m-$260.0M-211.6%-$184.0M-186.0%-$104.0M-1585.7%-$340.0M-1516.7%$233.0M-85.1%$214.0M+1326.7%
Dividends PaidN/AN/AN/AN/AN/AN/AN/A$0n/m
Share Buybacks$0n/mN/AN/AN/A$0N/AN/AN/A

BSX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BSX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin66.7%-3.2pp70.7%+3.1pp69.5%+0.6pp69.6%+1.7pp69.9%+1.1pp67.7%-1.5pp68.8%+0.2pp67.8%-1.4pp
Operating Margin16.1%-4.6pp21.6%+5.5pp21.2%+1.4pp15.6%+0.8pp20.7%+3.3pp16.2%+3.6pp19.8%+2.2pp14.8%-0.9pp
Net Margin11.3%-3.6pp16.7%+0.9pp25.8%+11.3pp12.7%+0.3pp14.9%+3.8pp15.8%+7.9pp14.4%+1.6pp12.4%-1.1pp
Return on Equity2.3%-1.0pp3.6%+0.1pp5.2%+2.1pp2.8%+0.2pp3.2%+1.0pp3.6%+2.0pp3.0%+0.6pp2.6%0.0pp
Return on Assets1.3%-0.5pp2.0%+0.1pp3.0%+1.3pp1.5%+0.1pp1.8%+0.5pp1.9%+1.0pp1.7%+0.3pp1.4%0.0pp
Current Ratio1.36-0.1x1.24-0.1x1.90+0.4x1.62+0.5x1.510.0x1.37-0.2x1.45-0.2x1.08-0.2x
Debt-to-Equity0.430.0x0.44-0.1x0.420.0x0.460.0x0.480.0x0.50+0.1x0.470.0x0.410.0x
Liabilities-to-Equity0.77-0.1x0.810.0x0.71-0.1x0.800.0x0.830.0x0.850.0x0.810.0x0.810.0x
Asset Turnover0.110.0x0.120.0x0.120.0x0.120.0x0.120.0x0.120.0x0.120.0x0.120.0x
FCF Margin16.9%-6.0pp23.5%+1.2pp3.3%-4.3pp19.2%-6.7pp22.9%+3.4pp22.3%+6.3pp7.6%+8.0pp25.8%+7.3pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Boston Scientific Corporation BSX FY2025 $20.1B $2.9B 14.4% $63.3B 66/100
Edwards Lifesciences Corp EW FY2025 $6.1B $1.1B 17.7% $60.5B 72/100
Stryker Corporation SYK FY2025 $25.1B $3.2B 12.9% $121.1B 69/100
GE HealthCare Technologies Inc. GEHC FY2025 $20.6B $2.1B 10.1% $37.8B 57/100
Medtronic plc MDT FY2026 $36.4B $4.8B 13.2% $128.8B 63/100
DexCom, Inc. DXCM FY2025 $4.7B $836.3M 17.9% $30.8B 74/100

Frequently Asked Questions

Boston Scientific Corporation (BSX) reported $20.1B in total revenue for fiscal year 2025. This represents a 19.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Boston Scientific Corporation (BSX) revenue grew by 19.9% year-over-year, from $16.7B to $20.1B in fiscal year 2025.

Yes, Boston Scientific Corporation (BSX) reported a net income of $3.5B over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $2.9B, with a net profit margin of 14.4%.

Boston Scientific Corporation (BSX) reported diluted earnings per share of $1.94 for fiscal year 2025. This represents a 55.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Boston Scientific Corporation (BSX) had EBITDA of $5.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Boston Scientific Corporation (BSX) had $2.0B in cash and equivalents against $11.1B in long-term debt.

Boston Scientific Corporation (BSX) had a gross margin of 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Boston Scientific Corporation (BSX) had an operating margin of 18.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Boston Scientific Corporation (BSX) had a net profit margin of 14.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Boston Scientific Corporation (BSX) has a return on equity of 12.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Boston Scientific Corporation (BSX) generated $3.7B in free cash flow during fiscal year 2025. This represents a 38.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Boston Scientific Corporation (BSX) generated $4.5B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Boston Scientific Corporation (BSX) had $43.7B in total assets as of fiscal year 2025, including both current and long-term assets.

Boston Scientific Corporation (BSX) invested $876.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Boston Scientific Corporation (BSX) invested $2.1B in research and development during fiscal year 2025.

Boston Scientific Corporation (BSX) had 1.48B shares outstanding as of fiscal year 2025.

Boston Scientific Corporation (BSX) had a current ratio of 1.62 as of fiscal year 2025, which is generally considered healthy.

Boston Scientific Corporation (BSX) had a debt-to-equity ratio of 0.46 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Boston Scientific Corporation (BSX) had a liabilities-to-equity ratio of 0.80 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Boston Scientific Corporation (BSX) had a return on assets of 6.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Boston Scientific Corporation (BSX) trades at 18.1x earnings, its market capitalization divided by $3.5B net income, trailing 12 months to September 30, 2026. The market capitalization is $63.3B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Boston Scientific Corporation (BSX) trades at 3.0x sales, its market capitalization divided by $21.1B revenue, trailing 12 months to September 30, 2026. The market capitalization is $63.3B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Boston Scientific Corporation (BSX) has an Altman Z-Score of 2.96, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Boston Scientific Corporation (BSX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Boston Scientific Corporation (BSX) has an earnings quality ratio of 1.56x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Boston Scientific Corporation (BSX) has an interest coverage ratio of 10.35x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Boston Scientific Corporation (BSX) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top